

02-33000-31

Original Effective Date: 02/15/02

Reviewed: 08/25/22

Revised: 09/15/22

## Subject: Treatments for Varicose Veins/Venous Insufficiency

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

A variety of treatment modalities are available to treat varicose veins/venous insufficiency, including surgery, thermal ablation, mechanochemical ablation (MOCA), cyanoacrylate adhesive (CAC), and sclerotherapy. The application of each modality is influenced by the severity of the symptoms, type of vein, source of venous reflux, and the use of other (prior or concurrent) treatment.

Treatment of venous reflux/venous insufficiency seeks to reduce abnormal pressure transmission from the deep to the superficial veins. Conservative medical treatment consists of elevation of the extremities, graded compression, and wound care when indicated. Conventional surgical treatment consists of identifying and correcting the site of reflux by ligation of the incompetent junction followed by stripping of the vein to redirect venous flow through veins with intact valves. While most venous reflux is secondary to incompetent valves at the saphenofemoral or saphenopopliteal junctions, reflux may also occur at incompetent valves in the perforator veins or the deep venous system. The competence of any single valve is not static and may be pressure-dependent. For example, accessory saphenous veins may have independent saphenofemoral or saphenopopliteal junctions that become incompetent when the great or small saphenous veins are eliminated, and blood flow is diverted through the accessory veins.

### POSITION STATEMENT:

**Great or Small Saphenous Veins**

Treatment of the great or small saphenous veins by surgery (ligation and stripping), endovenous radiofrequency, laser ablation, or microfoam sclerotherapy **meets the definition of medical necessity** for symptomatic varicose veins/venous insufficiency when the following criteria have been met:

- There is demonstrated saphenous reflux and CEAP (Clinical-Etiology-Anatomy-Pathophysiology) class C2\* or greater; **AND**
- The varicosities are at least 3 millimeters in size **AND**
- There is documentation of **one or more** of the following indications:
  1. Ulceration secondary to venous stasis; **OR**
  2. Recurrent superficial thrombophlebitis; **OR**
  3. Hemorrhage or recurrent bleeding episodes from a ruptured superficial varicosity; **OR**
  4. Persistent pain, swelling, itching, burning, or other symptoms are associated with saphenous reflux, **AND** the symptoms significantly interfere with activities of daily living, **AND** conservative management including compression therapy for at least 3 months has not improved the symptoms.

Treatment of great or small saphenous veins by surgery, endovenous radiofrequency, laser ablation, or microfoam sclerotherapy that do not meet the criteria described above is considered **cosmetic and does not meet the definition of medical necessity**.

### **Accessory Saphenous Veins**

Treatment of accessory saphenous veins by surgery (ligation and stripping), endovenous radiofrequency, laser ablation, or microfoam sclerotherapy, **meets the definition of medical necessity** for symptomatic varicose veins/venous insufficiency when the following criteria have been met:

- Incompetence of the accessory saphenous vein is isolated, or the great or small saphenous veins had been previously eliminated (at least 3 months); **AND**
- There is demonstrated accessory saphenous reflux; **AND**
- The varicosities are at least 3 millimeters in size **AND**
- There is documentation of **one or more** of the following indications:
  1. Ulceration secondary to venous stasis; **OR**
  2. Recurrent superficial thrombophlebitis; **OR**
  3. Hemorrhage or recurrent bleeding episodes from a ruptured superficial varicosity; **OR**
  4. Persistent pain, swelling, itching, burning, or other symptoms are associated with saphenous reflux, **AND** the symptoms significantly interfere with activities of daily living, **AND** conservative management including compression therapy for at least 3 months has not improved the symptoms.

Concurrent treatment of the accessory saphenous veins along with the great or small saphenous veins **meets the definition of medical necessity** when criteria is met for each vein and there is documentation of anatomy showing that the accessory saphenous vein discharged directly into the common femoral vein.

Treatment of accessory saphenous veins by surgery, endovenous radiofrequency, laser ablation, or microfoam sclerotherapy that do not meet the criteria described above is considered **cosmetic and does not meet the definition of medical necessity**.

## Symptomatic Varicose Tributaries

The following treatments **meet the definition of medical necessity** as a component of the treatment of symptomatic varicose tributaries when performed either at the same time or following prior treatment (surgical, radiofrequency, or laser) of the saphenous veins (none of these techniques has been shown to be superior to another):

- Stab avulsion
- Hook phlebectomy
- Sclerotherapy
- Transilluminated powered phlebectomy.

Treatment of symptomatic varicose tributaries, when performed either at the same time or following prior treatment of saphenous veins using any other techniques than those noted above, is considered **experimental or investigational**. The evidence is insufficient to determine the effects of the technology on health outcomes.

Ultrasound guidance for sclerotherapy of the varicose tributaries **does not meet the definition of medical necessity**. There is insufficient scientific evidence in peer-reviewed medical literature that ultrasound guidance has been proven to increase the effectiveness or safety of sclerotherapy for these veins.

## Perforator Veins

Surgical ligation (including subfascial endoscopic perforator surgery) or endovenous radiofrequency or laser ablation of incompetent perforator veins **meets the definition of medical necessity** as a treatment of leg ulcers associated with chronic venous insufficiency when **ALL** of the following conditions have been met:

- There is demonstrated perforator reflux; **AND**
- The varicosities are at least 3 millimeters in size **AND**
- The superficial saphenous veins (great, small, or accessory saphenous and symptomatic varicose tributaries) have been previously eliminated; **AND**
- Ulcers have not resolved following combined superficial vein treatment and compression therapy for at least 3 months; **AND**
- The venous insufficiency is not secondary to deep venous thromboembolism.

Ligation or ablation of incompetent perforator veins performed concurrently with superficial venous surgery **does not meet the definition of medical necessity**.

## Telangiectasia

Treatment of telangiectasia such as spider veins, angiomas, and hemangiomas is considered **cosmetic and does not meet the definition of medical necessity**.

## Other

Techniques for conditions not specifically listed above are considered **experimental or investigational**, including, but not limited to:

- Sclerotherapy techniques, other than microfoam sclerotherapy, of great, small, or accessory saphenous veins
- Sclerotherapy of perforator veins
- Sclerotherapy of isolated tributary veins without prior or concurrent treatment of saphenous veins
- Stab avulsion, hook phlebectomy, or transilluminated powered phlebectomy of perforator, great or small saphenous, or accessory saphenous veins
- Endovenous radiofrequency or laser ablation of tributary veins
- Endovenous cryoablation of any vein
- Mechanochemical ablation (MOCA) of any vein (e.g. ClariVein™ Catheter)
- Cyanoacrylate adhesive of any vein (e.g. VenaSeal Closure System)
- Conservative ambulatory hemodynamic correction of venous insufficiency (CHIVA).

The evidence is insufficient to permit conclusions on efficacy and net health outcomes.

**\* CEAP Clinical Classification System**

C0:	No visible or palpable signs of venous disease
C1:	Telangiectasies or reticular veins
C2:	Varicose veins
C2r:	Recurrent varicose veins
C3:	Edema
C4:	Changes in skin and subcutaneous tissue secondary to CVD
C4a:	Pigmentation and eczema
C4b:	Lipodermatosclerosis and atrophie blanche
C4c:	Corona phlebectatica
C5:	Healed venous ulcer
C6:	Active venous ulcer
C6r:	Recurrent active venous ulcer
S:	Symptoms including ache, pain, tightness, skin irritation, heaviness, muscle cramps, as well as other complaints attributable to venous dysfunction
A:	Asymptomatic

(Lurie, et al. The 2020 update of the CEAP classification system and reporting standards)

**BILLING/CODING INFORMATION:**

There is no specific CPT code for microfoam sclerotherapy. CPT codes describing sclerotherapy (36468-36471) may be used or the unlisted vascular surgery procedure code 37799. Use of codes 36475-36476 would be inappropriate because the procedure is not ablation therapy.

**CPT Coding:**

36465	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (eg, great saphenous vein, accessory saphenous vein)
-------	--

36466	Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (eg, great saphenous vein, accessory saphenous vein), same leg
36468	Injection(s) of sclerosant for spider veins (telangiectasia), limb or trunk <b>(Non-covered)</b>
36470	Injection of sclerosant; single incompetent vein (other than telangiectasia)
36471	Injection of sclerosant; multiple incompetent veins (other than telangiectasia), same leg
36473	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated <b>(Investigational)</b>
36474	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure) <b>(Investigational)</b>
36475	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated
36476	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; second and subsequent veins treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)
36478	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated
36479	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; second and subsequent veins treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)
36482	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; first vein treated <b>(Investigational)</b>
36483	Endovenous ablation therapy of incompetent vein, extremity, by transcatheter delivery of a chemical adhesive (eg, cyanoacrylate) remote from the access site, inclusive of all imaging guidance and monitoring, percutaneous; subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure) <b>(Investigational)</b>
37500	Vascular Endoscopy, surgical; with ligation of perforator veins, subfascial (SEPS)
37700	Ligation and division of long saphenous vein at saphenofemoral junction, or distal interruptions
37718	Ligation, division, and stripping, short saphenous vein
37722	Ligation, division, and stripping, long (greater) saphenous veins from saphenofemoral junction to knee or below
37735	Ligation and division and complete stripping of long or short saphenous veins with radical excision of ulcer and skin graft and/or interruption of communicating veins of lower leg, with excision of deep fascia

37760	Ligation of perforator veins, subfascial, radical (Linton type), including skin graft, when performed, open, 1 leg
37761	Ligation of perforator vein(s), subfascial, open, including ultrasound guidance, when performed, 1 leg
37765	Stab phlebectomy of varicose veins, 1 extremity; 10 – 20 stab incisions
37766	Stab phlebectomy of varicose veins, one extremity; more than 20 incisions
37780	Ligation and division of short saphenous vein at saphenopopliteal junction (separate procedure)
37785	Ligation, division, and/or excision of varicose vein cluster(s), 1 leg
0524T	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring ( <b>Investigational</b> )

Mechanochemical ablation may be billed with codes 37241 or 37244.

### HCPCS Coding:

S2202	Echosclerotherapy
-------	-------------------

### ICD-10 Diagnosis Codes That Support Medical Necessity:

I83.001 – I83.899	Varicose veins of lower extremities
I87.2	Venous, insufficiency (chronic) (peripheral)

### LOINC Codes:

The following information may be required documentation to support medical necessity: Physician history and physical, attending physician treatment plan, progress notes, and treatment notes including documentation of symptoms, failure of at least 3 consecutive months of medical management, and radiology reports (if applicable).

Documentation Table	LOINC Codes	LOINC Time Frame Modifier Code	LOINC Time Frame Modifier Codes Narrative
Physician history and physical	28626-0,	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Attending physician visit notes	18733-6	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.
Attending physician progress note	18741-9	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.

Treatment plan	18776-5	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim
Radiology	18726-0	18805-2	Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.

**REIMBURSEMENT INFORMATION:**

Sclerotherapy should be reported under codes 36470 for single vein or 36471 for multiple veins on the same leg. Code 36471 should be reported only once per leg.

Procedure codes 36475 and 36476 include the imaging guidance. Separate payment will not be made for imaging guidance reported with procedure codes 36475 or 36476. Code 36476 should be reported only once per leg.

Procedure codes 36478 and 36479 include imaging guidance. Separate payment will not be made for imaging guidance billed with procedure codes 36478 or 36479. Code 36479 should be reported only once per leg.

Procedure codes 37765 and 37766 should be reported only once per leg and should not be reported together.

Reimburse according to operative report.

**PROGRAM EXCEPTIONS:**

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage Products:** The following were reviewed on the last guideline reviewed date: Local Coverage Determination (LCD) Treatment of Chronic Venous Insufficiency of the Lower Extremities (L38720) and Local Coverage Article: Billing and Coding: Treatment of Chronic Venous Insufficiency of the Lower Extremities (A58250) located at fcso.com.

**DEFINITIONS:**

**Accessory saphenous vein:** A vein running in the thigh parallel to the great and small saphenous veins.

**Angiomata:** An abnormal growth due to the dilatation or new formation of blood vessels.

**Cyanoacrylate adhesive:** clear, free-flowing liquid that polymerizes in the vessel via an anionic mechanism (ie, polymerizes into a solid material upon contact with body fluids or tissue).

**Great saphenous vein:** the longest vein in the body, extending from the dorsum of the foot to just below the inguinal ligament, where it opens into the femoral vein. Also known as the long or large saphenous vein.

**Hemangiomas:** A benign tumor of blood vessels.

**Small saphenous vein:** the vein that continues the marginal vein from behind the malleolus and passes up the back of the leg to the knee joint, where it opens into the popliteal vein. Also known as the short or lesser saphenous vein.

**Perforator veins:** small veins that connect the superficial veins to the deep veins, allowing blood to drain from the skin into the deep veins and then pumped toward the heart.

**Superficial veins:** veins that run in the subcutaneous tissue in the lower limbs; the great saphenous vein and the small saphenous vein are the two major superficial veins. **Telangiectasia:** a type of varicose veins also known as spider veins; small bluish-purple veins, usually found in clusters on the leg.

**Tributaries:** veins that empty into larger veins.

## RELATED GUIDELINES:

[Durable Medical Equipment \(DME\), 09-E0000-01](#)

[Reconstructive Surgery/Cosmetic Surgery, 02-12000-01](#)

## OTHER:

None Applicable

## REFERENCES:

1. Almeida JI, Javier JJ, et al. Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. *J Vasc Surg Venous Lymphat Disord*. 2017 Sep;5(5):658-666.
2. Almeida JI, Murray SP, Romero ME. Saphenous Vein Histopathology 5.5 Years After Cyanoacrylate Closure. *J Vasc Surg Venous Lymphat Disord*. 2020 Mar;8(2):280-284. PMID:31281102. American Vein and Lymphatic Society. Position Statement Healthcare Policy Committee- Cyanoacrylate Venous Closure, revised February 28, 2019; available at [phlebology.org](http://phlebology.org).
3. American College of Phlebology. Superficial Venous Disease. 2015; accessed at [myavls.org](http://myavls.org) May 2021.
4. American Venous Forum, Revision of the CEAP Classification: Summary; accessed at [veinforum.org](http://veinforum.org).
5. Belramman A, Bootun R, et al. Pain Outcomes Following Mechanochemical Ablation vs Cyanoacrylate Adhesive for the Treatment of Primary Truncal Saphenous Vein Incompetence: The MOCCA Randomized Clinical Trial. *JAMA Surg*. 2022 May 1;157(5):395-404. PMID: 35385061.
6. Blue Cross Blue Shield Association Evidence Positioning System®, 7.01.124 Treatment of Varicose Veins/Venous Insufficiency, 06/22.
7. Chan YC, Law Y, et al. Predictors of recanalization for incompetent great saphenous veins treated with cyanoacrylate glue. *J Vasc Interv Radiol*. 2017;28(5):665-671. doi: 10.1016/j.jvir.2017.01.011. Epub 2017 Mar 8. PMID: 28284885.



8. ClinicalTrials.gov. Global, Post-Market, Prospective, Multi-Center, Randomized Controlled Trial of the VenaSeal™ ClosureSystem vs. Surgical Stripping or Endothermal Ablation (ETA) for the Treatment of Early & Advanced Stage Superficial Venous Disease; accessed May 2021.
9. ClinicalTrials.gov. Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins; accessed May 2021.
10. Dillavou ED, Kiguchi M. Comparison of methods for endovenous ablation for chronic venous disease. In UpToDate, Mills JL, Eit JF, Collins KA (Eds.), UpToDate, Waltham, MA; accessed at uptodate.com.
11. Dimech AP, Cassar K. Efficacy of Cyanoacrylate Glue Ablation of Primary Truncal Varicose Veins Compared to Existing Endovenous Techniques: A Systematic Review of the Literature. *Surg J (N Y)*. 2020 Jun 19;6(2):e77-e86. PMID:32577526.
12. Eroglu, E, Yasim, A. A Randomised Clinical Trial Comparing N-Butyl Cyanoacrylate, Radiofrequency Ablation and Endovenous Laser Ablation for the Treatment of Superficial Venous Incompetence: Two Year Follow up Results. *Eur J Vasc Endovasc Surg*. 2018 Oct;56(4):553-560.doi: 10.1016/j.ejvs.2018.05.028. PMID 30042039.
13. Eroglu E, Yasim A, et al. Mid-term results in the treatment of varicose veins with N-butyl cyanoacrylate. *Phlebology*. Dec 2017;32(10):665-669. PMID 28669248.
14. Farah MH, Nayfeh T, et al. A systematic review supporting the Society for Vascular Surgery, the American Venous Forum, and the American Vein and Lymphatic Society guidelines on the management of varicose veins. *J Vasc Surg Venous Lymphat Disord*. 2021 Aug 24;S2213-333X(21)00421-2. PMID: 34450355.
15. First Coast Service Options Inc. (FCSO). Local Coverage Article: Billing and Coding: Treatment of Chronic Venous Insufficiency of the Lower Extremities (A58250); accessed at fcso.com. First Coast Service Options Inc. (FCSO). Local Coverage Determination (LCD) Treatment of Chronic Venous Insufficiency of the Lower Extremities (L38720), accessed at fcso.com.
16. Garcia-Carpintero E, Carmona M, et al. Systematic review and meta-analysis of endovenous cyanoacrylate adhesive ablation for incompetent saphenous veins. *J Vasc Surg Venous Lymphat Disord*. 2020 Mar;8(2):287-296. PMID:31917181.
17. Gibson K, Ferris B. Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: Initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study). *Vascular*. Apr 2017;25(2):149-156.
18. Gibson K, Minjarez R, et al. Frequency and severity of hypersensitivity reactions in patients after VenaSeal™ cyanoacrylate treatment of superficial venous insufficiency. *Phlebology*. 2020 Jun;35(5):337-344. PMID:31554473.
19. Gibson K, Minjarez R, et al. Need for Adjunctive Procedures Following Cyanoacrylate Closure of Incompetent Great, Small and Accessory Saphenous Veins Without the Use of Postprocedure Compression: Three-month Data From a Postmarket Evaluation of the VenaSeal System (The WAVES Study). *Phlebology*. 2019 May;34(4):231-237.doi: 10.1177/0268355518801641. PMID: 30227791.
20. Gibson K, Morrison N, Kolluri R, et al. Twenty-four month results from a randomized trial of cyanoacrylate closure versus radiofrequency ablation for the treatment of incompetent great saphenous veins. *J Vasc Surg Venous Lymphat Disord* 2018; 6: 606–613. Epub 2018 Jun 15. PMID: 29914814.
21. Gloviczki P, Comerota AJ, et al, The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum, *J Vasc Surg*. 2011 May;53(5 Suppl):2S-48S; accessed at vascularweb.org 12/08/14.
22. Kalra M, Gloviczki P. Surgical treatment of venous ulcers: role of subfascial endoscopic perforator vein ligation. *Surg Clin North Am*. 2003 Jun; 83(3): 671-705.

23. Kiguchi MM, Reynolds KB, et al. The need for perforator treatment after VenaSeal and ClosureFast endovenous saphenous vein closure in CEAP 6 patients. *J Vasc Surg Venous Lymphat Disord*. 2021 Nov;9(6):1510-1516. PMID: 34111593.
24. Kim HS, Paxton BE. Endovenous laser ablation of the great saphenous vein with a 980-nm diode laser in continuous mode: early treatment failures and successful repeat treatments. *J Vasc Interv Radiol*. 2006 Sep; 17(9): 1449-55.
25. Kolluri R, Chung J, et al. Network Meta-Analysis to Compare VenaSeal With Other Superficial Venous Therapies for Chronic Venous Insufficiency. *J Vasc Surg Venous Lymphat Disord*. 2020 May;8(3):472-481.e3. doi: 10.1016/j.jvsv.2019.12.061. Epub 2020 Feb 14.
26. Kursat Bozkurt A, Lawaetz M, et al. European College of Phlebology guideline for truncal ablation. *Phlebology*. 2020 Mar;35(2):73-83. doi: 10.1177/0268355519857362. Epub 2019 Jun 27. PMID: 3128336.
27. Lam, YL, Lawson, JA, et al. Eight-year follow-up of a randomized clinical trial comparing ultrasound-guided foam sclerotherapy with surgical stripping of the great saphenous vein. *Br J Surg*. 2018 May;105(6):692-698. doi: 10.1002/bjs.10762. PMID 29652081.
28. Langridge BJ, Onida S, et al. Cyanoacrylate glue embolisation for varicose veins- A novel complication. *Phlebology*. 2020 Aug;35(7):520-523.
29. Lawrence PF, Hager ES, et al. Treatment of superficial and perforator reflux and deep venous stenosis improves healing of chronic venous leg ulcers. *J Vasc Surg Venous Lymphat Disord*. 2020 Jul;8(4):601-609. PMID: 32089497.
30. Lurie F, Passman M, et al. The 2020 update of the CEAP classification system and reporting standards. *J Vasc Surg Venous Lymphat Disord*. 2020 May;8(3):342-352. PMID: 32113854.
31. McGuinness B, Elias F, et al. comparison of duplex ultrasound findings after cyanoacrylate embolization versus endovenous laserablation of the great saphenous vein. *Vasc Surg Venous Lymphat Disord*. 2019 Nov;7(6):824-831. PMID:31495764.
32. Masuda E, Ozsvath K, et al. The 2020 appropriate use criteria for chronic lower extremity venous disease of the American Venous Forum, the Society for Vascular Surgery, the American Vein and Lymphatic Society, and the Society of Interventional Radiology. *J Vasc Surg Venous Lymphat Disord*. 2020 Jul;8(4):505-525.e4. PMID: 32139328.
33. Medtronic Vascular Inc. Dossier: VenaSeal™ Closure System, June 2022.
34. Mohamed AH, Leung C, et al. A Randomized Controlled Trial of Endovenous Laser Ablation Versus Mechanochemical Ablation With ClariVein in the Management of Superficial Venous Incompetence (LAMA Trial). *Ann Surg*. 2021 Jun 1;273(6):e188-e195. PMID:31977509.
35. Morrison N, Gibson K, et al. Five-year Extension Study of Patients From a Randomized Clinical Trial (VeClose) Comparing Cyanoacrylate Closure Versus Radiofrequency Ablation for the Treatment of Incompetent Great Saphenous Veins. *J Vasc Surg Venous Lymphat Disord*. 2020 Nov;8(6):978-989.
36. Morrison N, Gibson K, et al. VeClose trial 12-month outcomes of cyanoacrylate closure versus radiofrequency ablation for incompetent great saphenous veins. *J Vasc Surg Venous Lymphat Disord* 2017; 5: 321–330. doi: 10.1016/j.jvsv.2016.12.005. Epub 2017 Mar 6. PMID: 28411697.
37. Morrison N, Kolluri R, et al. Comparison of cyanoacrylate closure and radiofrequency ablation for the treatment of incompetent great saphenous veins: 36-Month outcomes of the VeClose randomized controlled trial. *Phlebology*. 2019 Jul;34(6):380-390.
38. National Institute for Health and Care Excellence (NICE). Cyanoacrylate Glue Occlusion for Varicose Veins Interventional Procedures Guidance, Published: 4 March 2020; accessed at nice.org.
39. National Institute for Health and Clinical Excellence (NICE). Endovenous laser treatment of the long saphenous vein; Interventional Procedure Guidance 2004:2 accessed at nice.org 05/21/12.

40. National Institute for Health and Clinical Excellence (NICE). Endovenous Mechanochemical Ablation for Varicose Veins, NICE interventional procedure guidance 435, 2016. Accessed at nice.org.
41. National Institute for Health and Clinical Excellence (NICE). Radiofrequency ablation of varicose veins, Interventional Procedure Guidance, 2003 accessed at nice.org.
42. National Institute for Health and Clinical Excellence (NICE). Subfascial endoscopic perforator vein surgery; Interventional Procedure Guidance, 2004:2 accessed at nice.org.
43. National Institute for Health and Clinical Excellence (NICE). Transilluminated powered phlebectomy for varicose veins; Interventional Procedure Guidance 2004:2; accessed at nice.org.
44. National Institute for Health and Clinic Excellence (NICE). Ultrasound-guided foam sclerotherapy for varicose veins; Interventional Procedure Guidance, 2009, accessed at nice.org.
45. National Institute for Health and Care Excellence (NICE). NICE Clinical Guideline 168: Varicose veins in the legs. 2013; accessed at nice.org.
46. Nyamekye IK. European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. *J Med Vasc.* 2022 Apr;47(2):53-55.
47. O'Banion LA, Reynolds KB, et al. A comparison of cyanoacrylate glue and radiofrequency ablation techniques in the treatment of superficial venous reflux in CEAP 6 patients. *J Vasc Surg Venous Lymphat Disord.* 2021 Sep;9(5):1215-1221. PMID: 33453440.
48. O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. *Cochrane Database of Systematic Reviews* 2009, Issue 1. Art. No.: CD000265. DOI:10.1002/14651858.CD000265.pub2.
49. Passman MA. Approach to treating symptomatic superficial venous insufficiency. In *UpToDate*, Eit JF, Mills JL, Collins KA (Eds.), *UpToDate*, Waltham, MA; accessed at uptodate.com.
50. Scovell S. Liquid, foam, and glue sclerotherapy techniques for the treatment of lower extremity veins. In *UpToDate*, Eit JF, Mills JL, Dover JS, Collins KA (Eds.), *UpToDate*, Waltham, MA; accessed at uptodate.com.
51. Tang TY, Qi Yap CJ, et al. Early results (3 months) of an Asian prospectivemulticenter VenaSeal real-world postmarketevaluation to investigate the efficacy and safety ofcyanoacrylate endovenous ablation for varicose veins. *J Vasc Surg Venous Lymphat Disord.* 2020 May 7;S2213-33X(20)30238-9. PMID:32387378.
52. Tenbrook JA Jr, Iafrafi MD, O'donnell TF Jr, Wolf MP, Hoffman SN, Pauker SG, Lau J, Wong JB. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. *J Vasc Surg.* 2004 Mar; 39(3): 583-9.
53. U.S. Food and Drug Administration (FDA); accessed at fda.gov.
54. Vähäaho, S, Mahmoud, O, et al. Randomized clinical trial of mechanochemical and endovenous thermal ablation of great saphenous varicose veins. *Br J Surg.* 2019 Apr;106(5):548-554. Doi: 10.1002/bjs.11158. PMID 30908611.
55. van der Velden SK, Biemans AA, De Maeseneer MG, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. *Br J Surg.* Jul 1 2015.
56. Vasquez M, Gasparis AP, Varithena 017 Investigator G. A multicenter, randomized, placebo-controlled trial of endovenous thermal ablation with or without polidocanol endovenous microfoam treatment in patients with great saphenous vein incompetence and visible varicosities. *Phlebology.* May 2017;32(4):272-281.
57. Weaver I, Weaver P. Audit of the efficacy and complications ofcyanoacrylate glue embolisation to treat varicoseveins in primary care. *JPrim Health Care.* 2019 Sep;11(3):249-258. PMID:32171378.

58. Whing J, Nandhra S, et al. Interventions for great saphenous vein incompetence. Cochrane Database of Systematic Reviews 2021, Issue 8. Art. No.: CD005624. DOI: 10.1002/14651858.CD005624.pub4; accessed at [cochranelibrary.com](http://cochranelibrary.com).
59. Yang GK, Parapini M, et al. Comparison of cyanoacrylate embolization and radiofrequency ablation for the treatment of varicose veins. *Phlebology*. 2019 May;34(4):278-283. PMID:30114987.
60. Zierau UT. VenaSeal®-Closure: Results Over 6 Years Treatment. A follow-Up Study Conducted on 1950 Truncal Saphenous Veins in 1061 Cases. *J Vasc Endovasc Therapy*. 2018 Vol.3 No.3:14.

## COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the BCBSF Medical Policy and Coverage Committee on 08/25/22.

## GUIDELINE UPDATE INFORMATION:

02/15/02	04-77260-16 Endoluminal Radiofrequency Ablation for Varicose Veins approved.
07/15/02	Revised to remove limitation for sclerotherapy; Renamed to include other treatments for varicose veins; Renumbered from 04-77260-16 to 02-33000-13.
01/01/03	HCPCS coding update.
06/15/03	Reviewed; no change in coverage.
12/15/03	Sodium tetradecyl sulfate removed from MCG.
04/15/04	Review and revision of guideline consisting of updated references, added coverage statement for laser ablation, and added information about SEPS and Transilluminated Powered Phlebectomy (investigational). These additions led to the archiving of guideline: Subfascial Endoscopic Perforator Surgery (SEPS).
01/01/05	Annual HCPCS update; consisting of the deletion of S2130 and S2131 and addition of 36475, 36476, 36478 and 36479.
04/15/05	Review and revision of guideline; consisting of updated references, added coverage statement for Transilluminated powered phlebectomy.
04/15/06	Review and revision of guideline consisting of updated references.
11/15/06	Revision of guideline.
03/15/07	Review and revision of guideline consisting of updated references.
06/15/07	Reformatted guideline.
05/15/09	Biennial review: position statements and criteria revised; description section, reimbursement information, Medicare Advantage section and references updated.
01/01/10	Annual HCPCS coding review: added code 37761 & revised code descriptors for 37760 & 37765 located in the Program Exceptions section under the Medicare Advantage Products.
02/15/10	Revision: additional position statements added regarding sclerotherapy; reimbursement and definition sections updated.
10/15/10	Revision; related ICD-10 codes added.
02/15/11	Revision; formatting changes.
08/15/11	Revision; formatting changes.
10/01/11	Revision; formatting changes.

07/12/12	Annual review; position statements, billing/coding, Medicare program exception, and references updated; formatting changes.
10/15/12	Revision; Accessory saphenous veins position statement and definitions updated; formatting changes.
07/15/13	Annual review; position statement section and references updated; formatting changes.
05/15/14	Annual review; position statements maintained and references updated.
01/01/15	Annual HCPCS/CPT update. Removed code 36469.
02/15/15	Annual review; position statements and references updated; formatting changes.
10/01/15	Revision; ICD10 coding section updated.
11/01/15	Revision: ICD-9 Codes deleted.
02/15/16	Revision; description, position statement section and references updated; formatting changes.
03/23/16	Revision; reimbursement section updated.
05/15/16	Revision to Position Statement.
08/01/16	Revision: Reimbursement Section.
10/01/16	Revision; formatting changes.
01/01/17	Annual CPT/HCPCS update. Added 36473, 36474; revised 36476, 36479.
07/15/17	Revision; position statement section updated to include CHIVA method; references updated.
01/01/18	Annual CPT/HCPCS update. Added codes 36465, 36466, 36482, 36483; revised codes 36468, 36470, 36471.
09/15/18	Review; description, position statement, reimbursement information, and references updated.
01/01/19	Annual CPT/HCPCS coding update. Added code 0524T.
07/15/19	Revision; position statement and references updated.
01/15/20	Review; investigational position for cyanoacrylate adhesive maintained.
07/15/20	Review; position statements maintained and references updated.
12/15/20	Review; position statements maintained and references updated.
01/01/21	Annual CPT/HCPCS update. Code 76970 deleted.
07/15/21	Review; Position statements maintained and references updated.
09/15/22	Review: Position statements maintained; references updated.